Vyne Financial Statements From 2010 to 2025

VYNE Stock  USD 2.65  0.15  5.36%   
Vyne Therapeutics financial statements provide useful quarterly and yearly information to potential Vyne Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Vyne Therapeutics financial statements helps investors assess Vyne Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Vyne Therapeutics' valuation are summarized below:
Gross Profit
477 K
Market Capitalization
44.3 M
Enterprise Value Revenue
10.0433
Revenue
486 K
Earnings Share
1.72
There are over one hundred nineteen available fundamental trend indicators for Vyne Therapeutics, which can be analyzed over time and compared to other ratios. Investors should ensure to double-check all of Vyne Therapeutics' current performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road. As of February 26, 2025, Market Cap is expected to decline to about 9.4 M. The current year's Enterprise Value is expected to grow to about (24.8 M)

Vyne Therapeutics Total Revenue

463,220

Check Vyne Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vyne Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 13 M, Selling General Administrative of 26.8 M or Other Operating Expenses of 58.3 M, as well as many indicators such as Price To Sales Ratio of 61.67, Dividend Yield of 0.0 or PTB Ratio of 0.25. Vyne financial statements analysis is a perfect complement when working with Vyne Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Vyne Therapeutics Correlation against competitors.
For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.

Vyne Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets82 M112.3 M67.8 M
Slightly volatile
Other Current Liabilities5.6 M6.6 M3.7 M
Slightly volatile
Total Current Liabilities10.9 M8.7 M7.1 M
Slightly volatile
Accounts Payable3.3 M1.9 M2.2 M
Slightly volatile
Cash36.6 M35.2 M36.9 M
Pretty Stable
Cash And Short Term Investments70.3 M107.2 M60.7 M
Slightly volatile
Common Stock Total Equity2.4 K4.6 K2.3 K
Slightly volatile
Common Stock Shares Outstanding12.4 M11.8 M2.8 M
Slightly volatile
Liabilities And Stockholders Equity82 M112.3 M67.8 M
Slightly volatile
Non Current Liabilities Total1.2 M1.3 M38.6 M
Slightly volatile
Other Current Assets3.6 M3.1 M2.3 M
Slightly volatile
Total Liabilities7.7 M8.1 M42.7 M
Slightly volatile
Total Current Assets78.4 M110.4 M65.6 M
Slightly volatile
Common Stock1.1 K1.1 K93.5 K
Pretty Stable
Other Liabilities997.5 K884.4 K687.3 K
Slightly volatile
Net Tangible Assets48.6 M28.1 M82.1 M
Slightly volatile
Property Plant And Equipment Net226.1 K238.1 K286.1 K
Slightly volatile
Current Deferred Revenue19.1 M18.2 M7.9 M
Slightly volatile
Non Current Assets Total2.9 M1.5 M6.1 M
Slightly volatile
Other Assets1.9 M2.9 M1.3 M
Slightly volatile
Net Receivables5.3 M5.9 M4.4 M
Slightly volatile
Non Current Liabilities Other1.6 M1.5 M523.5 K
Slightly volatile
Short Term Debt98.3 K103.5 K689.2 K
Pretty Stable
Property Plant Equipment302.7 K318.6 K1.2 M
Very volatile
Net Working Capital55 M79.6 M63 M
Pretty Stable
Short and Long Term Debt Total183 K192.6 K2.7 M
Pretty Stable
Long Term Debt26.5 M29.9 M32.6 M
Slightly volatile
Good Will3.6 M4.1 M4.5 M
Slightly volatile

Vyne Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative26.8 M15.4 M16.9 M
Slightly volatile
Other Operating Expenses58.3 M34.1 M37 M
Slightly volatile
Research Development30.9 M18.8 M19.8 M
Slightly volatile
Total Operating Expenses57.7 M34.1 M36.7 M
Slightly volatile
Interest Income3.7 M3.6 M1.8 M
Slightly volatile
Total Revenue463.2 K487.6 K3.7 M
Pretty Stable
Gross Profit362.5 K381.6 K3.3 M
Pretty Stable
Cost Of RevenueM3.9 M1.4 M
Slightly volatile

Vyne Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation5.6 M3.8 M3.5 M
Slightly volatile
Begin Period Cash Flow34.8 M35.6 M22.3 M
Slightly volatile
End Period Cash Flow36.8 M35.3 M37 M
Pretty Stable
Issuance Of Capital Stock312.9 K329.4 K79.6 M
Slightly volatile
Dividends Paid251.4 K264.6 K21.3 M
Slightly volatile
Other Cashflows From Investing Activities17.1 M14.1 M17.1 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio61.6764.92259
Slightly volatile
Days Sales Outstanding3.6 K3.4 KK
Slightly volatile
Stock Based Compensation To Revenue7.377.023.3962
Slightly volatile
Capex To Depreciation0.360.384.1294
Slightly volatile
Inventory Turnover0.240.410.2998
Slightly volatile
Days Of Inventory On Hand1.5 K9141.3 K
Slightly volatile
Payables Turnover0.240.460.2164
Slightly volatile
Sales General And Administrative To Revenue16.628.3916.9734
Slightly volatile
Research And Ddevelopement To Revenue23.0234.6124.2473
Pretty Stable
Capex To Revenue0.00590.00620.025
Slightly volatile
Cash Per Share9.9210.44171
Slightly volatile
Days Payables Outstanding7758162.8 K
Slightly volatile
Income Quality0.660.80.8377
Very volatile
Net Debt To EBITDA1.771.24.0615
Slightly volatile
Current Ratio14.6114.6427.1094
Slightly volatile
Receivables Turnover0.10.113.3102
Slightly volatile
Graham Number25.3526.68329
Pretty Stable
Capex Per Share0.06850.07220.1455
Slightly volatile
Revenue Per Share0.04510.04756.1783
Pretty Stable
Operating Cycle3.6 K3.4 K1.3 K
Slightly volatile
Days Of Payables Outstanding7758162.8 K
Slightly volatile
Ebt Per Ebit0.910.861.0509
Very volatile
Long Term Debt To Capitalization0.380.420.4608
Slightly volatile
Quick Ratio14.5514.6427.0746
Slightly volatile
Net Income Per E B T0.790.920.9553
Pretty Stable
Cash Ratio4.444.6723.3269
Slightly volatile
Days Of Inventory Outstanding1.5 K9141.3 K
Slightly volatile
Days Of Sales Outstanding3.6 K3.4 KK
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.151.022
Slightly volatile
Fixed Asset Turnover2.242.3629.4797
Pretty Stable
Price Sales Ratio61.6764.92259
Slightly volatile
Asset Turnover0.00370.00390.0456
Pretty Stable
Gross Profit Margin0.510.70.4101
Slightly volatile

Vyne Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap9.4 M9.9 M215.7 M
Slightly volatile

Vyne Fundamental Market Drivers

Cash And Short Term Investments93.3 M

Vyne Upcoming Events

14th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Vyne Therapeutics Financial Statements

Vyne Therapeutics stakeholders use historical fundamental indicators, such as Vyne Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Vyne Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Vyne Therapeutics' assets and liabilities are reflected in the revenues and expenses on Vyne Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Vyne Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue18.2 M19.1 M
Total Revenue487.6 K463.2 K
Cost Of Revenue3.9 MM
Stock Based Compensation To Revenue 7.02  7.37 
Sales General And Administrative To Revenue 28.39  16.60 
Research And Ddevelopement To Revenue 34.61  23.02 
Capex To Revenue 0.01  0.01 
Revenue Per Share 0.05  0.05 
Ebit Per Revenue(79.36)(83.32)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Vyne Therapeutics is a strong investment it is important to analyze Vyne Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Vyne Therapeutics' future performance. For an informed investment choice regarding Vyne Stock, refer to the following important reports:
Check out the analysis of Vyne Therapeutics Correlation against competitors.
For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vyne Therapeutics. If investors know Vyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
1.72
Revenue Per Share
0.016
Quarterly Revenue Growth
0.467
Return On Assets
(0.35)
Return On Equity
(0.60)
The market value of Vyne Therapeutics is measured differently than its book value, which is the value of Vyne that is recorded on the company's balance sheet. Investors also form their own opinion of Vyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vyne Therapeutics' market value can be influenced by many factors that don't directly affect Vyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.